GlassScriptPhysician profile
Nather B Ansari
NPI 1689663320
$14,085.60
in general payments reported to CMS, 2019-2025
65 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,314 · 2020: $1,802 · 2021: $2,069 · 2022: $1,683 · 2023: $1,975 · 2024: $1,738 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,850 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,850.24 |
| Education | $367.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,643.40 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,144.54 | 2019-2025 | |
| Lilly USA, LLC | $1,042.98 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Astrazeneca Pharmaceuticals LP | $990.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $879.35 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $846.70 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $771.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $769.97 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $547.07 | 2019-2023 | Xarelto |
| Melinta Therapeutics, LLC | $525.48 | 2019-2024 | Kimyrsa, Rezzayo |
| Novartis Pharmaceuticals Corporation | $486.72 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $303.80 | 2021-2025 | |
| Allergan, INC. | $275.37 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $237.11 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nather Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.